Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial.

scientific article published in September 2005

Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1001/JAMA.294.10.1215
P698PubMed publication ID16160130
P5875ResearchGate publication ID7603051

P50authorStephen G. EllisQ62496584
Jeffrey PopmaQ87844791
Gregg W StoneQ90754539
Douglas SpriggsQ114292220
Joerg KoglinQ114321707
J Tift MannQ114444150
Samuel DeMaioQ114445138
P2093author name stringMary E Russell
Louis Cannon
Charles D O'Shaughnessy
Patrick Hall
Joel D Greenberg
TAXUS V Investigators
P433issue10
P407language of work or nameEnglishQ1860
P921main subjectcoronary artery diseaseQ844935
P304page(s)1215-1223
P577publication date2005-09-01
P1433published inThe Journal of the American Medical AssociationQ1470970
P1476titleComparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial.
P478volume294

Reverse relations

cites work (P2860)
Q37438436A Comparison of Peri-Procedural Myocardial Infarction between Paclitaxel-Coated Balloon and Drug-Eluting Stent on De Novo Coronary Lesions.
Q37385456A comparison of bare-metal and drug-eluting stents for off-label indications
Q47161708A comparison of the main outcomes from BP-BES and DP-DES at five years of follow-up: A systematic review and meta-analysis
Q36954581A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease
Q33677854A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: design and statistical methods of the PERSEUS clinical program
Q55424383A rare complication of percutaneous coronary intervention: Coronary pseudoaneurysm formation.
Q36680683Adjunctive pharmacotherapy for coronary interventions-time to read the writing on the wall
Q36614126An overview of the TAXUS Express, paclitaxel-eluting stent clinical trial program
Q35670480Analysis of potential cost-savings after introduction of drug-eluting balloon angioplasty for in-stent restenosis or small vessel disease
Q37435155Angiographic results of the cobalt chromium Vision and Mini-Vision stents
Q93379484Antiplatelet agents in uncertain clinical scenarios-a bleeding nightmare
Q34731151Are "treatment" bare metal stents superior to "control" bare metal stents? A meta-analytic approach
Q37458616Automated surveillance to detect postprocedure safety signals of approved cardiovascular devices
Q85555592Bare Metal Stents Versus Drug Eluting Stents: Where Do We Stand in 2015?
Q33833003Bayesian design of noninferiority trials for medical devices using historical data
Q44995869Biofunctionalization of titanium surface with multilayer films modified by heparin-VEGF-fibronectin complex to improve endothelial cell proliferation and blood compatibility
Q47296986Blinded sample size recalculation in clinical trials with binary composite endpoints
Q58752931Cardiovascular stents: overview, evolution, and next generation
Q36940822Characterizing the spectrum of in-stent restenosis: implications for contemporary treatment
Q46944476Chronic kidney disease and the risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents
Q33770283Clinical Implication of Optical Coherence Tomography-Based Neoatherosclerosis
Q35146546Clinical and angiographic outcomes after intracoronary bare-metal stenting
Q43015474Clinical and angiographic outcomes of drug-eluting stents in patients with large vessel and single coronary artery lesion.
Q38265084Clinical outcome of drug-eluting versus bare-metal stents in patients with calcified coronary lesions: a meta-analysis
Q35579187Clinical performance of biodegradable versus permanent polymer drug-eluting stents: A meta-analysis of randomized clinical trials at long-term follow-up
Q46090522Comparable clinical safety and efficacy of biodegradable versus durable polymer paclitaxel eluting stents despite shorter dual antiplatelet therapy: insights from a multicenter, propensity score-matched registry
Q28551554Comparing the Clinical Outcomes between Drug Eluting Stents and Bare Metal Stents in Patients with Insulin-Treated Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials
Q33661362Comparison of Drug-Eluting Balloon Followed by Bare Metal Stent with Drug-Eluting Stent for Treatment of de Novo Lesions: Randomized, Controlled, Single-Center Clinical Trial.
Q51679181Comparison of Long-Term Outcomes in Real-World Patients Between Resolute Zotarilumus-Eluting and Paclitaxel-Eluting Stents in Small Vessel.
Q36687927Comparison of a drug-eluting balloon first and then bare metal stent with a drug-eluting stent for treatment of de novo lesions: study protocol of a randomized controlled trial
Q44206351Comparison of drug-eluting and bare metal stents in large coronary arteries: findings from the NHLBI dynamic registry
Q43235841Comparison of long-term outcomes following sirolimus-eluting stent vs paclitaxel-eluting stent implantation in patients with long calcified coronary lesions
Q39717689Comparison of long-term outcomes of bare-metal and paclitaxel-eluting stents in New York
Q51097849Comparison of the slow-release polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions.
Q64242473Contemporary Management of Stent Failure: Part One
Q38079934Controversies in the use & implementation of drug-eluting stent technology.
Q33718126Coronary Aneurysm Formation After Bioresorbable Vascular Scaffold Implantation Resulting in Acute Myocardial Infarction
Q41057555Coronary stents and vascular response to implantation: literature review
Q83477274Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease
Q43725719Cost-effectiveness of paclitaxel-coated balloon angioplasty in patients with drug-eluting stent restenosis.
Q55005923Current Management of In-Stent Restenosis.
Q38224405Current and future perspectives on drug-eluting bioresorbable coronary scaffolds
Q37558450Current issues in coronary stent technology
Q37799356Current status of the Xience V® everolimus-eluting coronary stent system.
Q37952250Current status, challenges and future directions of drug-eluting balloons
Q36654328Cypher versus Taxus: the stent war.
Q36968009Delivery of large biopharmaceuticals from cardiovascular stents: a review
Q46030040Development of biodegradable drug releasing polymeric cardiovascular stents and in vitro evaluation.
Q50919067Discrepancy between computed tomography coronary angiography and selective coronary angiography in the pre-stenting assessment of coronary lesion length.
Q36282710Drug eluting stents: an updated meta-analysis of randomised controlled trials
Q38028877Drug-coated balloons for coronary and peripheral interventional procedures
Q38037077Drug-eluting coronary stents - focus on improved patient outcomes
Q48028885Drug-eluting coronary stents: as safe as bare-metal stents, but optimized antiplatelet therapy may further improve clinical outcome
Q34091036Drug-eluting stents
Q37874693Drug-eluting stents and balloons in peripheral arterial disease: evidence so far.
Q37577872Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment
Q37788985Drug-eluting stents in the elderly
Q24186681Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes
Q24235466Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes
Q37445860Drug-eluting stents: a comprehensive appraisal
Q37141941Drug-eluting stents: a review of current evidence on clinical effectiveness and late complications
Q38162864Drug-eluting versus bare-metal coronary stents: where are we now?
Q31102731Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study
Q28219713Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study
Q35139482Effect of imatinib mesylate and rapamycin on the preformed intimal hyperplasia in rat carotid injury model
Q53517409Effect of oxide layer modification of CoCr stent alloys on blood activation and endothelial behavior.
Q34753360Effectiveness of drug-eluting stents versus bare-metal stents in large coronary arteries in patients with acute myocardial infarction
Q45975445Efficacy and safety of a double-coated paclitaxel-eluting coronary stent: the EUCATAX trial.
Q34319885Efficacy and safety of drug-eluting stents in the real world: 8-year follow-up.
Q45071262Emerging Technologies in Flow Diverters and Stents for Cerebrovascular Diseases
Q46073499Everolimus-eluting stents and zotarolimus-eluting stents for percutaneous coronary interventions: two-year outcomes in New York State
Q44317798Evolution of stents: past, present and future
Q46293725Extended follow-up following "full-metal jacket" percutaneous coronary interventions with drug-eluting stents
Q37016139FDA advisory panel on the safety and efficacy of drug-eluting stents: summary of findings and recommendations
Q42360036First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study
Q37314517Frequency of Vascular Inflammation and Impact on Neointimal Proliferation of Drug Eluting Stents in Porcine Coronary Arteries.
Q50458420Inhibition of restenosis formation without compromising reendothelialization as a potential solution to thrombosis following angioplasty?
Q38931805Inhibitory effects of roscovitine on proliferation and migration of vascular smooth muscle cells in vitro
Q46093927Interoperator and intraoperator (in)accuracy of stent selection based on visual estimation
Q39651758Intractable intraoperative bleeding requiring platelet transfusion during emergent cholecystectomy in a patient with dual antiplatelet therapy after drug-eluting coronary stent implantation (with video).
Q93646608JournalScan
Q50944358Lessons learned in the drug-eluting stent era.
Q43411274Local delivery of sirolimus nanoparticles for the treatment of in-stent restenosis
Q37765610Local drug delivery for treatment of coronary and peripheral artery disease
Q26767320Long-term clinical outcomes of everolimus-eluting stent versus paclitaxel-eluting stent in patients undergoing percutaneous coronary interventions: a meta-analysis
Q48226488Long-term follow-up of the platinum chromium TAXUS Element (ION) stent: The PERSEUS Workhorse and Small Vessel trial five-year results.
Q39876546Low coronary flow velocity and shear stress predict restenosis after sirolimus-eluting stent implantation
Q37858604Low stent thrombosis risk with the XIENCE V® Everolimus-Eluting Coronary Stent: evidence from randomized and single-arm clinical trials
Q44707694Management of multivessel coronary disease: let us not shortchange drug-eluting stents
Q56638730Medikamente freisetzende Koronarstents und mit Medikamenten beschichtete Ballonkatheter
Q41633062Mid-Term Follow-Up of Drug-Eluting Stenting for In-Stent Restenosis: Bare-Metal Stents versus Drug-Eluting Stents
Q28081589Multifaceted prospects of nanocomposites for cardiovascular grafts and stents
Q41927383Multiple sequential complications after sirolimus-eluting stent implantation: very late stent thrombosis, stent fracture, in-stent restenosis, and peri-stent aneurysm
Q36836467Myocardial revascularization: surgery or stenting?
Q33576893Nanomedicine for the reduction of the thrombogenicity of stent coatings.
Q36654375New developments in coronary stent technology
Q36160441New stent design for use in small coronary arteries during percutaneous coronary intervention
Q37998111New technologies aimed at percutaneous intervention in the small coronary artery
Q37399954Nickel-free stainless steel avoids neointima formation following coronary stent implantation
Q45340209Nine-month angiographic and intravascular ultrasound outcomes after resolute zotarolimus-eluting stent implantation for the treatment of in-stent restenosis
Q37887771Nitric oxide: a guardian for vascular grafts?
Q37269384Off-label use of stents: bare-metal versus drug-eluting stents
Q36614131Off-label use: an industry perspective on expanding use beyond approved indications
Q44305034One-year clinical outcome of a randomized trial of polymer-free paclitaxel-eluting stents versus biodegradable polymer-based rapamycin-eluting stents in patients with coronary heart disease
Q40080241One-year outcome of small-vessel disease treated with sirolimus-eluting stents: a subgroup analysis of the e-SELECT registry
Q37851899Optical coherence tomography endpoints in stent clinical investigations: strut coverage
Q37522553Organ transplantation and drug eluting stents: Perioperative challenges
Q36942534Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
Q35354402Outcomes of small coronary artery stenting with bare-metal stents versus drug-eluting stents: results from the NHLBI Dynamic Registry
Q36154232Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials.
Q36614116Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent
Q42548668Paclitaxel-Coated Balloons: Investigation of Drug Transfer in Healthy and Atherosclerotic Arteries - First Experimental Results in Rabbits at Low Inflation Pressure
Q44130145Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis
Q37608478Paclitaxel-eluting stents
Q37878377Pathogenesis of implant-associated infection: the role of the host
Q37629184Percutaneous Coronary Intervention: Safety of Methotrexate and Its Possible Benefits on Restenosis After Bare-Metal Stent Deployment
Q37786640Percutaneous coronary intervention for small-vessel coronary disease: highlight on the everolimus-eluting stent
Q37720739Percutaneous coronary intervention using a full metal jacket with drug-eluting stents: major adverse cardiac events at one year
Q38084549Perioperative management of antiplatelet therapy in patients with drug-eluting stents.
Q37782048Periprocedural Myocardial Infarction: Review and Classification
Q38241974Pharmacological inhibition of coronary restenosis: systemic and local approaches
Q37756979Pharmacological prevention and management of restenosis
Q40099411Planned versus provisional rotational atherectomy for severe calcified coronary lesions: Insights From the ROTATE multi-center registry
Q53494401Predictors of coronary artery aneurysm after stent implantation in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Q41486571Predictors of diffuse-type in-stent restenosis following drug-eluting stent implantation
Q43046171Procedure-related myonecrosis after bare and drug-eluting stent implantation
Q36684479Promoting vascular regeneration as an alternative to conventional angioplasty-based intervention
Q47914004Prospective randomized trial comparing a nitinol self-expanding coronary stent with low-pressure dilatation and a high-pressure balloon expandable bare metal stent
Q45398663Racial differences in long-term outcomes after percutaneous coronary intervention with paclitaxel-eluting coronary stents
Q38634385Real-Time Electrical Bioimpedance Characterization of Neointimal Tissue for Stent Applications.
Q47217489Restenosis in coronary bare metal stents. Importance of time to follow-up: a comparison of coronary angiograms 6 months and 4 years after implantation
Q36486769Restenosis related to percutaneous coronary intervention has been solved?
Q37373342Retractable-needle catheters: an update on local drug delivery in coronary interventions
Q37244760Revascularization treatment recommendations based on atherosclerotic disease distribution: coronary artery bypass grafting versus stenting
Q36759494Review of the TAXUS Liberté SR paclitaxel-eluting coronary stent
Q92792658Safety and Efficacy of a New Ultrathin Sirolimus-Eluting Stent with Abluminal Biodegradable Polymer in Real-World Practice
Q41834012Safety and efficacy of a non-polymeric paclitaxel-eluting microporous stent in real-world percutaneous coronary intervention
Q37044202Safety and efficacy of a novel iopromide-based paclitaxel-eluting balloon following bare metal stent implantation in rabbit aorta abdominalis
Q46529943Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials
Q57730945Safety of drug-coated stents
Q37139276Safety of drug-eluting stents
Q51310341Same or Different Drug-Eluting Stent Re-Implantation for Drug-Eluting Stent Restenosis: An Assessment Including Second-Generation Drug-Eluting Stents.
Q34662245Second- versus first-generation drug-eluting stents for diabetic patients: a meta-analysis
Q48200963Selection of composite binary endpoints in clinical trials
Q41488676Sensor to detect endothelialization on an active coronary stent
Q47433386Short-term follow-up results of drug-eluting stenting in premature coronary artery disease patients with multiple atherosclerotic risk factors
Q35707420Sirolimus-eluting dextran and polyglutamic acid hybrid coatings on AZ31 for stent applications.
Q37807873Small coronary vessel angioplasty: outcomes and technical considerations
Q34134537Smooth muscle cell-specific insulin-like growth factor-1 overexpression in Apoe-/- mice does not alter atherosclerotic plaque burden but increases features of plaque stability
Q41962888Stent thrombosis: incidence, predictors and new technologies
Q37691815Surface modification of a polyhedral oligomeric silsesquioxane poly(carbonate-urea) urethane (POSS-PCU) nanocomposite polymer as a stent coating for enhanced capture of endothelial progenitor cells.
Q41848327Surgical treatment for coronary artery aneurysm: a single-centre experience
Q33553921Survival advantage in Medicare patients receiving drug-eluting stents compared with bare metal stents: real or artefactual?
Q52718141TAK-733 inhibits inflammatory neointimal formation by suppressing proliferation, migration, and inflammation in vitro and in vivo.
Q36117819The Food and Drug Administration and pragmatic clinical trials of marketed medical products
Q38310049The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view
Q36225762The power prior: theory and applications
Q28200757The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease
Q40097851Thrombosis after stent implantation: how much of a problem is there?
Q57130197Towards a self-reporting coronary artery stent—Measuring neointimal growth associated with in-stent restenosis using electrical impedance techniques
Q51054146Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter.
Q40534372Treatment of drug-eluting stent restenosis: Comparison between drug-eluting balloon versus second-generation drug-eluting stents from a retrospective observational study
Q38376537Treatment of small coronary arteries with a paclitaxel-coated balloon catheter
Q42853401Two-year clinical outcomes after large coronary stent (4.0 mm) placement: comparison of bare-metal stent versus drug-eluting stent.
Q49934946Two-year results after coronary stenting of small vessels in Japanese population using 2.25-mm diameter sirolimus-eluting stent with bioresorbable polymer: primary and long-term outcomes of CENTURY JSV study.
Q46405787Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions
Q38558645Understanding the Outcome of Randomized Trials with Drug-Eluting Stents and Coronary Artery Bypass Graft in Patients with Multivessel Disease: A Review of a 25-Year Journey
Q47133703Undesired Outcomes of the Catania Stent Compared to the Xience Stent in Patients Undergoing Angioplasty: A Double-Blind Randomized Controlled Trial
Q36985317Update on stents: recent studies on the TAXUS stent system in small vessels.
Q33571243Update on the everolimus-eluting coronary stent system: results and implications from the SPIRIT clinical trial program.
Q38864003Usage patterns and 1-year outcomes with the TAXUS Liberté stent: results of the TAXUS OLYMPIA registry
Q53971688Utility of drug-eluting stents in complex lesions and high-risk patients.
Q37472070Xience V everolimus-eluting coronary stent
Q83901875[New developments in drug-eluting stents]

Search more.